The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 379-389

  Heusinkveld, Moniek ^a   Welters, Marij J P ^a   Van Poelgeest, Mariette I E ^a   Van Der Hulst, Jeanette M ^a   Melief, Cornelis J M ^a   Fleuren, Gert Jan J ^a   Kenter, Gemma G ^a   Van Der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cervical cancer; human papillomavirus; immunity; prognosis; T cells

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN; HLA DQ ANTIGEN; HLA DQ06 ANTIGEN; HLA DR13 ANTIGEN; HLA DR15 ANTIGEN; HLA DR7 ANTIGEN; INTERLEUKIN 10; PROTEIN E6; PROTEIN E7; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER INVASION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMETRY; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNE STATUS; MAJOR CLINICAL STUDY; NETHERLANDS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS IMMUNITY;

ADULT; AGED; CYTOKINES; FEMALE; GENES, MHC CLASS II; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; UTERINE CERVICAL NEOPLASMS;

EID: 78649579110     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25361     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD,. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8.
3. zur Hausen H,. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-F78.
4. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R,. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 472-9.
5. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH,. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64: 5449-55.
6. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63: 636-41.
7. van den Hende M, van Poelgeest MI, van der Hulst JM, de Jong J, Drijfhout JW, Fleuren GJ, Valentijn AR, Wafelman AR, Slappendel GM, Melief CJ, Offringa R, van der Burg SH, et al. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. Int J Cancer 2008; 123: 146-52.
8. Kenter GG, Welters MJP, Valentijn AR, Lowik MJG, Berends-van der Meer D, Vloon APG, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
9. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, Scheper RJ, Stacey SN, Duggan-Keen MF, Stern PL, Man S, Borysiewicz LK, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000; 88: 92-8.
10. de Vos van Steenwijk PJ, Piersma SJ, Welters MJ, van der Hulst JM, Fleuren G, Hellebrekers BW, Kenter GG, van der Burg SH,. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. Clin Cancer Res 2008; 14: 7188-95.
11. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R,. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007; 104: 12087-92.
12. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH,. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007; 67: 354-61.
13. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJ, van der Burg SH,. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009; 15: 6341-47.
14. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ,. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14: 2028-35.
15. Bontkes HJ, van Duin M, de Gruijl TD, Duggan-Keen MF, Walboomers JM, Stukart MJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ, Stevens FR, Dyer PA, et al. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer 1998; 78: 166-71.
16. Ghaderi M, Wallin KL, Wiklund F, Zake LN, Hallmans G, Lenner P, Dillner J, Sanjeevi CB,. Risk of invasive cervical cancer associated with polymorphic HLA DR/DQ haplotypes. Int J Cancer 2002; 100: 698-701.
17. Hildesheim A, Wang SS,. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89: 229-40.
18. Krul EJ, Schipper RF, Schreuder GM, Fleuren GJ, Kenter GG, Melief CJ,. HLA and susceptibility to cervical neoplasia. Hum Immunol 1999; 60: 337-42.
19. Singh N, Arif S,. Histopathologic parameters of prognosis in cervical cancer-a review. Int J Gynecol Cancer 2004; 14: 741-50.
20. Claas EC, Melchers WJ, van der Linden HC, Lindeman J, Quint WG,. Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. Am J Pathol 1989; 135: 703-9.
21. Verduyn W, Doxiadis II, Anholts J, Drabbels JJ, Naipal A, D'Amaro J, Persijn GG, Giphart MJ, Schreuder GM,. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol 1993; 37: 59-67.
22. van der Burg SH, Ressing ME, Kwappenberg KM, de JA, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001; 91: 612-18.
23. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, Offringa R, van der Burg SH,. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int.J Cancer 2008; 122: 486-94.
24. Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M,. HLA gene and haplotype frequencies in Dutch blood donors. Tissue Antigens 1996; 48: 562-74.
25. Ayhan A, Celik H, Dursun P, Gultekin M, Yuce K,. Prognostic and therapeutic importance of lymphadenectomy in gynecological cancers. Eur J Gynaecol Oncol 2004; 25: 279-86.
26. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM,. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994; 6: 157-62.
27. Welters MJ, van der Logt P, van den Eeden SJ, Kwappenberg KM, Drijfhout JW, Fleuren GJ, Kenter GG, Melief CJ, van der Burg SH, Offringa R,. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006; 118: 950-6.
28. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14: 178-87.
29. Piersma SJ, Welters MJ, van der Burg SH,. Tumor-specific regulatory T cells in cancer patients. Hum Immunol 2008; 69: 241-9.
30. Bignone PA, Banham AH,. FOXP3+ regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther 2008; 8: 1897-1920.
31. Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, Scambia G, Fattorossi A,. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 2009; 58: 1363-73.
32. Delgado FG, Martinez E, Cespedes MA, Bravo MM, Navas MC, Combita Rojas AL,. Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy. Immunology 2009; 126: 523-34.
33. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002; 8: 3676-85.
34. Visser J, van Baarle D, Hoogeboom BN, Reesink N, Klip H, Schuuring E, Nijhuis E, Pawlita M, Bungener L, de Vries-Idema J, Nijman H, Miedema F, et al. Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. Int J Cancer 2006; 118: 2529-37.
35. Herfs M, Herman L, Hubert P, Minner F, Arafa M, Roncarati P, Henrotin Y, Boniver J, Delvenne P,. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother 2009; 58: 603-14.
36. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S,. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007; 98: 874-81.
37. van Oijen M, Bins A, Elias S, Sein J, Weder P, de Gast G, Mallo H, Gallee M, van Tinteren H, Schumacher T, Haanen J,. On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res 2004; 10: 4754-60.
38. Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJ, van den Eertwegh AJ, Scheper RJ, von Blomberg ME, Bontkes HJ,. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007; 121: 1749-55.
39. Visser J, Nijman HW, Hoogenboom BN, Jager P, van Baarle D, Schuuring E, Abdulahad W, Miedema F, van der Zee AG, Daemen T,. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 2007; 150: 199-209.
40. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J, Ueno H,. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA 2007; 104: 20884-9.